Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10983928 | 0.85 | MAPT (0.40) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21296895 | 0.84 | AKR1C3 (0.47) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22795573 | 0.83 | ALDH1A1 (0.41) | KDM4EGAAEGFRP2RY14 | |
| SCHEMBL21296876 | 0.81 | CASP3 (0.48) | SMN1; SMN2MEN1KMT2AKDM4ENPC1 | |
| SCHEMBL11340745 | 0.75 | EP300 (0.42) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23001832 | 0.72 | HAO1 (0.65) | NPC1 | |
| SCHEMBL22772699 | 0.71 | RAB9A (0.41) | SMN1; SMN2KMT2AKDM4ENPC1MAPT | |
| SCHEMBL21312466 | 0.71 | RAB9A (0.41) | SMN1; SMN2KMT2AKDM4ENPC1MAPT | |
| SCHEMBL23001720 | 0.71 | MAPT (0.50) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL21296965 | 0.69 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EGAANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | AKR1C3 334/4885AKR1C2 290/4885SMN1; SMN2 3163/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | AKR1C3 334/4885AKR1C2 290/4885SMN1; SMN2 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.